Andrew Morris
Concepts (491)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Lysophospholipids | 25 | 2020 | 44 | 5.770 |
Why?
| Phosphatidate Phosphatase | 10 | 2024 | 14 | 2.520 |
Why?
| Sphingosine | 11 | 2018 | 28 | 1.500 |
Why?
| Phosphoric Diester Hydrolases | 9 | 2019 | 33 | 1.260 |
Why?
| Signal Transduction | 13 | 2020 | 1608 | 1.230 |
Why?
| Polychlorinated Biphenyls | 9 | 2018 | 25 | 1.100 |
Why?
| Environmental Pollutants | 5 | 2020 | 92 | 1.040 |
Why?
| Polyisoprenyl Phosphates | 4 | 2014 | 13 | 1.010 |
Why?
| Ceramides | 8 | 2024 | 31 | 0.990 |
Why?
| Inflammation | 4 | 2020 | 603 | 0.950 |
Why?
| Animals | 57 | 2024 | 13100 | 0.870 |
Why?
| Streptomyces | 9 | 2016 | 10 | 0.840 |
Why?
| Lipid Metabolism | 3 | 2013 | 175 | 0.830 |
Why?
| Cardiovascular Diseases | 4 | 2024 | 445 | 0.810 |
Why?
| Muscle, Smooth, Vascular | 2 | 2020 | 131 | 0.750 |
Why?
| Diet | 4 | 2024 | 553 | 0.750 |
Why?
| Mice | 38 | 2024 | 5658 | 0.720 |
Why?
| Atherosclerosis | 4 | 2019 | 210 | 0.720 |
Why?
| Fluorocarbons | 1 | 2020 | 49 | 0.680 |
Why?
| Hyperlipidemias | 1 | 2019 | 51 | 0.650 |
Why?
| Phosphoric Monoester Hydrolases | 5 | 2015 | 21 | 0.640 |
Why?
| Adipogenesis | 3 | 2018 | 49 | 0.600 |
Why?
| Mice, Inbred C57BL | 19 | 2019 | 1777 | 0.530 |
Why?
| Plaque, Atherosclerotic | 2 | 2014 | 39 | 0.530 |
Why?
| Molecular Structure | 13 | 2020 | 293 | 0.510 |
Why?
| Homeostasis | 5 | 2018 | 202 | 0.490 |
Why?
| Protein Prenylation | 2 | 2013 | 5 | 0.460 |
Why?
| Farnesol | 1 | 2013 | 4 | 0.450 |
Why?
| Mevalonic Acid | 1 | 2013 | 5 | 0.450 |
Why?
| Diterpenes | 1 | 2013 | 30 | 0.440 |
Why?
| Phosphotransferases (Alcohol Group Acceptor) | 5 | 2014 | 21 | 0.440 |
Why?
| Sesquiterpenes | 2 | 2013 | 88 | 0.430 |
Why?
| Mast Cells | 1 | 2013 | 54 | 0.420 |
Why?
| Tandem Mass Spectrometry | 4 | 2020 | 227 | 0.420 |
Why?
| Glucose | 5 | 2018 | 337 | 0.420 |
Why?
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2013 | 137 | 0.400 |
Why?
| Sphingomyelin Phosphodiesterase | 3 | 2019 | 11 | 0.400 |
Why?
| Adipocytes | 4 | 2018 | 121 | 0.390 |
Why?
| Enzyme Inhibitors | 5 | 2015 | 378 | 0.390 |
Why?
| Sphingolipids | 3 | 2018 | 15 | 0.380 |
Why?
| Antineoplastic Agents | 2 | 2013 | 1175 | 0.370 |
Why?
| Humans | 40 | 2024 | 49929 | 0.360 |
Why?
| Nuclear Localization Signals | 1 | 2010 | 6 | 0.360 |
Why?
| Phosphatidic Acids | 1 | 2010 | 6 | 0.360 |
Why?
| Mice, Knockout | 11 | 2019 | 835 | 0.340 |
Why?
| Obesity | 6 | 2018 | 1096 | 0.330 |
Why?
| Endoplasmic Reticulum | 1 | 2010 | 118 | 0.320 |
Why?
| Adipose Tissue | 5 | 2019 | 188 | 0.320 |
Why?
| Antifungal Agents | 3 | 2016 | 343 | 0.320 |
Why?
| Nuclear Proteins | 1 | 2010 | 242 | 0.320 |
Why?
| Phospholipase D | 2 | 2010 | 7 | 0.310 |
Why?
| Membrane Proteins | 3 | 2015 | 347 | 0.310 |
Why?
| Cardiovascular Physiological Phenomena | 1 | 2008 | 12 | 0.310 |
Why?
| Dioxins | 2 | 2018 | 10 | 0.310 |
Why?
| Diet, High-Fat | 4 | 2015 | 214 | 0.310 |
Why?
| Chromatography, Liquid | 2 | 2020 | 225 | 0.300 |
Why?
| Insulin Resistance | 4 | 2018 | 255 | 0.290 |
Why?
| Cell Movement | 6 | 2013 | 245 | 0.290 |
Why?
| Methylamines | 2 | 2018 | 17 | 0.290 |
Why?
| Oxazoles | 2 | 2016 | 8 | 0.280 |
Why?
| Anti-Bacterial Agents | 4 | 2016 | 742 | 0.280 |
Why?
| Oxidative Stress | 5 | 2015 | 759 | 0.270 |
Why?
| Glycosides | 2 | 2016 | 18 | 0.270 |
Why?
| Oligopeptides | 2 | 2016 | 93 | 0.260 |
Why?
| Neuroprotective Agents | 2 | 2016 | 101 | 0.260 |
Why?
| Multidrug Resistance-Associated Proteins | 2 | 2015 | 16 | 0.260 |
Why?
| Cells, Cultured | 7 | 2019 | 1587 | 0.260 |
Why?
| Liver | 4 | 2016 | 1106 | 0.260 |
Why?
| Glutathione | 3 | 2015 | 296 | 0.250 |
Why?
| S-Adenosylmethionine | 2 | 2016 | 62 | 0.250 |
Why?
| Hydrolysis | 4 | 2019 | 63 | 0.250 |
Why?
| Neoplasms | 2 | 2024 | 1234 | 0.250 |
Why?
| Aging | 2 | 2024 | 669 | 0.250 |
Why?
| Drug Design | 4 | 2015 | 119 | 0.240 |
Why?
| Lipoproteins, LDL | 2 | 2019 | 169 | 0.240 |
Why?
| Antibiotics, Antineoplastic | 2 | 2015 | 77 | 0.240 |
Why?
| Phenols | 2 | 2016 | 79 | 0.240 |
Why?
| Aminoglycosides | 2 | 2015 | 18 | 0.230 |
Why?
| Blood Platelets | 3 | 2012 | 249 | 0.230 |
Why?
| Peptides, Cyclic | 2 | 2014 | 42 | 0.230 |
Why?
| Doxorubicin | 2 | 2015 | 233 | 0.220 |
Why?
| Apolipoproteins E | 2 | 2014 | 55 | 0.220 |
Why?
| Endothelial Cells | 4 | 2014 | 256 | 0.220 |
Why?
| Chromatography, High Pressure Liquid | 3 | 2020 | 326 | 0.220 |
Why?
| Receptors, Purinergic | 2 | 2019 | 14 | 0.220 |
Why?
| Sarcopenia | 1 | 2024 | 91 | 0.210 |
Why?
| Stem Cells | 2 | 2015 | 172 | 0.210 |
Why?
| Receptors, Cell Surface | 1 | 2003 | 120 | 0.210 |
Why?
| Focal Adhesions | 2 | 2013 | 14 | 0.210 |
Why?
| Spectrometry, Mass, Electrospray Ionization | 3 | 2018 | 60 | 0.200 |
Why?
| Receptors, Lysophosphatidic Acid | 3 | 2016 | 5 | 0.200 |
Why?
| Glucocorticoids | 1 | 2024 | 229 | 0.200 |
Why?
| Cell Line, Tumor | 7 | 2013 | 1388 | 0.200 |
Why?
| Enzymes | 2 | 2013 | 30 | 0.190 |
Why?
| Muscle, Skeletal | 2 | 2024 | 769 | 0.180 |
Why?
| Solid Phase Extraction | 1 | 2020 | 12 | 0.180 |
Why?
| Myocardial Infarction | 2 | 2015 | 391 | 0.180 |
Why?
| Plasma | 1 | 2020 | 42 | 0.170 |
Why?
| Inulin | 1 | 2019 | 9 | 0.170 |
Why?
| Male | 19 | 2024 | 25454 | 0.170 |
Why?
| Nucleotides | 2 | 2014 | 24 | 0.170 |
Why?
| Hypolipidemic Agents | 1 | 2019 | 28 | 0.170 |
Why?
| HeLa Cells | 4 | 2016 | 257 | 0.170 |
Why?
| Ovarian Neoplasms | 1 | 2003 | 450 | 0.160 |
Why?
| Molecular Sequence Data | 3 | 2015 | 799 | 0.160 |
Why?
| Glucosides | 2 | 2015 | 13 | 0.160 |
Why?
| Peptides | 2 | 2016 | 220 | 0.150 |
Why?
| Hematopoietic Stem Cell Mobilization | 2 | 2015 | 56 | 0.150 |
Why?
| Receptors, Aryl Hydrocarbon | 2 | 2015 | 25 | 0.150 |
Why?
| Myocardium | 3 | 2015 | 443 | 0.150 |
Why?
| Up-Regulation | 3 | 2016 | 446 | 0.150 |
Why?
| Mutation | 2 | 2013 | 1292 | 0.150 |
Why?
| Bone Marrow Cells | 2 | 2015 | 190 | 0.140 |
Why?
| Curcumin | 1 | 2017 | 18 | 0.140 |
Why?
| Sequence Alignment | 2 | 2010 | 121 | 0.140 |
Why?
| NF-E2-Related Factor 2 | 3 | 2013 | 40 | 0.140 |
Why?
| Deuterium | 2 | 2016 | 43 | 0.140 |
Why?
| Ethers | 1 | 2016 | 8 | 0.140 |
Why?
| Obesity, Morbid | 1 | 2018 | 74 | 0.140 |
Why?
| Insulin | 3 | 2018 | 453 | 0.140 |
Why?
| Cell Nucleus | 2 | 2015 | 186 | 0.140 |
Why?
| Naphthoquinones | 2 | 2013 | 10 | 0.140 |
Why?
| Lipoproteins | 1 | 2016 | 39 | 0.140 |
Why?
| Oxygenases | 1 | 2016 | 14 | 0.130 |
Why?
| Choline | 1 | 2016 | 63 | 0.130 |
Why?
| Steroids | 1 | 2016 | 56 | 0.130 |
Why?
| HEK293 Cells | 5 | 2016 | 216 | 0.130 |
Why?
| Durapatite | 1 | 2015 | 24 | 0.130 |
Why?
| Bile Acids and Salts | 1 | 2016 | 76 | 0.130 |
Why?
| Nuclear Magnetic Resonance, Biomolecular | 4 | 2017 | 30 | 0.130 |
Why?
| Dietary Fats | 2 | 2016 | 124 | 0.130 |
Why?
| Terphenyl Compounds | 1 | 2015 | 1 | 0.130 |
Why?
| Hexuronic Acids | 1 | 2015 | 5 | 0.130 |
Why?
| Uridine | 1 | 2015 | 6 | 0.130 |
Why?
| Drug Carriers | 1 | 2015 | 69 | 0.130 |
Why?
| Lipoprotein Lipase | 1 | 2015 | 12 | 0.120 |
Why?
| Hematopoietic Stem Cells | 2 | 2014 | 182 | 0.120 |
Why?
| Cohort Studies | 1 | 2019 | 1403 | 0.120 |
Why?
| Serine C-Palmitoyltransferase | 1 | 2015 | 6 | 0.120 |
Why?
| Vancomycin | 1 | 2015 | 80 | 0.120 |
Why?
| Multigene Family | 1 | 2015 | 56 | 0.120 |
Why?
| Glucuronides | 1 | 2015 | 45 | 0.120 |
Why?
| Mitochondria | 1 | 2018 | 395 | 0.120 |
Why?
| Myocytes, Smooth Muscle | 2 | 2012 | 85 | 0.120 |
Why?
| Drug Resistance, Bacterial | 1 | 2015 | 72 | 0.120 |
Why?
| RNA, Messenger | 3 | 2014 | 1099 | 0.120 |
Why?
| Pyrrolidonecarboxylic Acid | 1 | 2014 | 1 | 0.120 |
Why?
| Thiazolidines | 1 | 2014 | 5 | 0.120 |
Why?
| Antioxidants | 2 | 2013 | 234 | 0.120 |
Why?
| Streptomyces antibioticus | 1 | 2014 | 1 | 0.120 |
Why?
| Receptors, Steroid | 1 | 2014 | 19 | 0.120 |
Why?
| Glycosyltransferases | 1 | 2014 | 12 | 0.120 |
Why?
| Carbohydrate Metabolism | 1 | 2014 | 26 | 0.120 |
Why?
| Osteomyelitis | 1 | 2015 | 125 | 0.120 |
Why?
| Methionine Adenosyltransferase | 1 | 2014 | 19 | 0.120 |
Why?
| Cell Proliferation | 3 | 2013 | 986 | 0.120 |
Why?
| Weight Loss | 2 | 2015 | 241 | 0.120 |
Why?
| Macrophages | 3 | 2014 | 361 | 0.120 |
Why?
| Archaeal Proteins | 1 | 2014 | 15 | 0.110 |
Why?
| Capillary Permeability | 1 | 2014 | 35 | 0.110 |
Why?
| Sulfolobus solfataricus | 1 | 2014 | 21 | 0.110 |
Why?
| Amines | 1 | 2014 | 39 | 0.110 |
Why?
| Macrolides | 1 | 2013 | 16 | 0.110 |
Why?
| Rifabutin | 1 | 2013 | 5 | 0.110 |
Why?
| Pyrones | 1 | 2013 | 8 | 0.110 |
Why?
| Isocitrate Dehydrogenase | 1 | 2013 | 17 | 0.110 |
Why?
| Tea | 1 | 2013 | 17 | 0.110 |
Why?
| Benzoxazoles | 1 | 2013 | 11 | 0.110 |
Why?
| Hydroxymethylglutaryl CoA Reductases | 1 | 2013 | 9 | 0.110 |
Why?
| Actinobacteria | 1 | 2013 | 8 | 0.110 |
Why?
| Phosphodiesterase Inhibitors | 1 | 2013 | 25 | 0.110 |
Why?
| Benzhydryl Compounds | 1 | 2014 | 66 | 0.110 |
Why?
| Chromans | 1 | 2013 | 35 | 0.110 |
Why?
| Rhamnose | 1 | 2013 | 5 | 0.110 |
Why?
| Half-Life | 1 | 2013 | 85 | 0.110 |
Why?
| Inflammation Mediators | 2 | 2014 | 110 | 0.110 |
Why?
| Stilbenes | 1 | 2013 | 54 | 0.110 |
Why?
| Methyltransferases | 1 | 2013 | 29 | 0.110 |
Why?
| Tissue Distribution | 1 | 2013 | 163 | 0.110 |
Why?
| Gene Expression Regulation, Enzymologic | 1 | 2014 | 178 | 0.110 |
Why?
| Cysteine | 1 | 2013 | 50 | 0.110 |
Why?
| Thionucleosides | 1 | 2012 | 2 | 0.110 |
Why?
| Antimicrobial Cationic Peptides | 1 | 2013 | 28 | 0.110 |
Why?
| Ubiquitination | 1 | 2013 | 40 | 0.110 |
Why?
| Adenosine Monophosphate | 1 | 2012 | 15 | 0.110 |
Why?
| Risk | 1 | 2014 | 314 | 0.110 |
Why?
| Anion Transport Proteins | 1 | 2012 | 4 | 0.110 |
Why?
| Central Nervous System Neoplasms | 1 | 2013 | 64 | 0.110 |
Why?
| Receptors, Lipoprotein | 1 | 2012 | 7 | 0.110 |
Why?
| Carotid Artery Injuries | 1 | 2012 | 13 | 0.110 |
Why?
| Glioma | 1 | 2013 | 76 | 0.110 |
Why?
| Lymph | 1 | 2012 | 24 | 0.100 |
Why?
| Base Sequence | 3 | 2015 | 657 | 0.100 |
Why?
| Diacylglycerol Kinase | 1 | 2012 | 5 | 0.100 |
Why?
| Human Umbilical Vein Endothelial Cells | 1 | 2013 | 90 | 0.100 |
Why?
| Piperazines | 1 | 2013 | 118 | 0.100 |
Why?
| Disease Models, Animal | 4 | 2024 | 1411 | 0.100 |
Why?
| Platelet Activation | 1 | 2012 | 47 | 0.100 |
Why?
| Adenosine | 1 | 2012 | 70 | 0.100 |
Why?
| Purinergic P2Y Receptor Antagonists | 1 | 2012 | 29 | 0.100 |
Why?
| Erucic Acids | 1 | 2012 | 1 | 0.100 |
Why?
| Ubiquitin-Protein Ligases | 1 | 2013 | 93 | 0.100 |
Why?
| Regeneration | 1 | 2013 | 72 | 0.100 |
Why?
| Neurites | 1 | 2012 | 13 | 0.100 |
Why?
| Neurogenesis | 1 | 2012 | 24 | 0.100 |
Why?
| Hepatocytes | 1 | 2013 | 179 | 0.100 |
Why?
| ATP-Binding Cassette Transporters | 1 | 2012 | 34 | 0.100 |
Why?
| Autophagy | 1 | 2013 | 165 | 0.100 |
Why?
| Axons | 1 | 2012 | 45 | 0.100 |
Why?
| Insulin-Secreting Cells | 1 | 2012 | 23 | 0.100 |
Why?
| Protein Binding | 4 | 2016 | 656 | 0.100 |
Why?
| Glucose Intolerance | 1 | 2012 | 27 | 0.100 |
Why?
| Protein Phosphatase 1 | 1 | 2011 | 7 | 0.100 |
Why?
| RNA Precursors | 1 | 2011 | 9 | 0.100 |
Why?
| Pyridinium Compounds | 1 | 2011 | 20 | 0.100 |
Why?
| Hematocrit | 1 | 2011 | 43 | 0.100 |
Why?
| Fibroblasts | 2 | 2012 | 352 | 0.100 |
Why?
| Adipose Tissue, Brown | 1 | 2012 | 40 | 0.100 |
Why?
| Erythrocyte Transfusion | 1 | 2011 | 50 | 0.100 |
Why?
| Integrins | 1 | 2011 | 30 | 0.100 |
Why?
| Tumor Suppressor Protein p53 | 1 | 2013 | 213 | 0.100 |
Why?
| Alternative Splicing | 1 | 2011 | 57 | 0.100 |
Why?
| Anemia | 1 | 2011 | 66 | 0.090 |
Why?
| Catechin | 1 | 2011 | 12 | 0.090 |
Why?
| Phenotype | 4 | 2015 | 728 | 0.090 |
Why?
| Heme Oxygenase-1 | 1 | 2011 | 18 | 0.090 |
Why?
| Caveolin 1 | 1 | 2011 | 21 | 0.090 |
Why?
| Platelet Aggregation Inhibitors | 1 | 2012 | 174 | 0.090 |
Why?
| Eicosapentaenoic Acid | 1 | 2010 | 20 | 0.090 |
Why?
| Docosahexaenoic Acids | 1 | 2010 | 27 | 0.090 |
Why?
| Genetic Predisposition to Disease | 1 | 2014 | 508 | 0.090 |
Why?
| Exercise | 1 | 2015 | 493 | 0.090 |
Why?
| alpha Karyopherins | 1 | 2010 | 1 | 0.090 |
Why?
| Active Transport, Cell Nucleus | 1 | 2010 | 33 | 0.090 |
Why?
| Amidines | 1 | 2010 | 8 | 0.090 |
Why?
| Liposomes | 1 | 2010 | 52 | 0.090 |
Why?
| Group V Phospholipases A2 | 1 | 2010 | 1 | 0.090 |
Why?
| Membrane Lipids | 1 | 2010 | 13 | 0.090 |
Why?
| rho GTP-Binding Proteins | 1 | 2010 | 6 | 0.090 |
Why?
| Macrophage Activation | 1 | 2010 | 25 | 0.090 |
Why?
| Coronary Artery Disease | 1 | 2014 | 272 | 0.090 |
Why?
| Cholesterol, LDL | 1 | 2010 | 36 | 0.090 |
Why?
| Cerebellum | 1 | 2011 | 132 | 0.090 |
Why?
| Colonic Neoplasms | 1 | 2011 | 158 | 0.090 |
Why?
| Mice, Inbred BALB C | 1 | 2010 | 296 | 0.080 |
Why?
| Recombinant Fusion Proteins | 1 | 2010 | 186 | 0.080 |
Why?
| Kinetics | 3 | 2016 | 632 | 0.080 |
Why?
| Astrocytes | 1 | 2011 | 146 | 0.080 |
Why?
| Time Factors | 4 | 2012 | 2891 | 0.080 |
Why?
| Boronic Acids | 1 | 2010 | 182 | 0.080 |
Why?
| Models, Molecular | 3 | 2016 | 334 | 0.080 |
Why?
| Amino Acid Sequence | 1 | 2010 | 579 | 0.080 |
Why?
| Magnetic Resonance Spectroscopy | 3 | 2015 | 244 | 0.080 |
Why?
| Catalysis | 3 | 2014 | 89 | 0.080 |
Why?
| Neurons | 1 | 2012 | 455 | 0.080 |
Why?
| Colorectal Neoplasms | 1 | 2012 | 253 | 0.080 |
Why?
| Interleukin-6 | 1 | 2010 | 265 | 0.080 |
Why?
| Substrate Specificity | 3 | 2014 | 192 | 0.080 |
Why?
| RNA, Small Interfering | 3 | 2015 | 210 | 0.080 |
Why?
| Mice, Transgenic | 3 | 2015 | 543 | 0.080 |
Why?
| Leukocytes | 1 | 2008 | 66 | 0.080 |
Why?
| Protein Structure, Tertiary | 3 | 2016 | 249 | 0.080 |
Why?
| Rats | 4 | 2016 | 3273 | 0.080 |
Why?
| Tumor Necrosis Factor-alpha | 1 | 2010 | 388 | 0.080 |
Why?
| Female | 9 | 2024 | 26576 | 0.070 |
Why?
| Hematopoietic Stem Cell Transplantation | 1 | 2013 | 555 | 0.070 |
Why?
| CHO Cells | 3 | 2013 | 121 | 0.070 |
Why?
| Cricetinae | 3 | 2013 | 211 | 0.070 |
Why?
| Phosphorylation | 3 | 2015 | 526 | 0.070 |
Why?
| Cell Differentiation | 1 | 2010 | 649 | 0.070 |
Why?
| Structure-Activity Relationship | 3 | 2014 | 394 | 0.070 |
Why?
| Glutathione Disulfide | 2 | 2015 | 40 | 0.060 |
Why?
| Appalachian Region | 2 | 2016 | 12 | 0.060 |
Why?
| Down-Regulation | 2 | 2019 | 342 | 0.060 |
Why?
| Crystallography, X-Ray | 2 | 2016 | 148 | 0.060 |
Why?
| Autoimmune Diseases | 1 | 2024 | 81 | 0.060 |
Why?
| Catalytic Domain | 2 | 2014 | 57 | 0.060 |
Why?
| Reverse Transcription | 1 | 2003 | 4 | 0.060 |
Why?
| Suramin | 1 | 2003 | 13 | 0.060 |
Why?
| Phospholipases A | 1 | 2003 | 14 | 0.060 |
Why?
| Phospholipases A2 | 1 | 2003 | 15 | 0.060 |
Why?
| Random Allocation | 2 | 2016 | 285 | 0.050 |
Why?
| Gene Expression Regulation | 3 | 2012 | 964 | 0.050 |
Why?
| Receptors, Lysosphingolipid | 2 | 2013 | 5 | 0.050 |
Why?
| Polymerase Chain Reaction | 2 | 2015 | 456 | 0.050 |
Why?
| Glucose Tolerance Test | 2 | 2013 | 56 | 0.050 |
Why?
| NAD(P)H Dehydrogenase (Quinone) | 2 | 2013 | 13 | 0.050 |
Why?
| Phosphatidylinositol 4,5-Diphosphate | 2 | 2013 | 10 | 0.050 |
Why?
| Cell Division | 1 | 2003 | 294 | 0.050 |
Why?
| Tumor Cells, Cultured | 1 | 2003 | 462 | 0.050 |
Why?
| Cricetulus | 2 | 2013 | 107 | 0.050 |
Why?
| Thiazolidinediones | 2 | 2015 | 82 | 0.050 |
Why?
| Recombinant Proteins | 2 | 2015 | 482 | 0.050 |
Why?
| Adenosine Triphosphate | 1 | 2003 | 231 | 0.050 |
Why?
| Mass Spectrometry | 2 | 2013 | 283 | 0.050 |
Why?
| Platelet Aggregation | 2 | 2012 | 71 | 0.050 |
Why?
| Enzyme Activation | 2 | 2012 | 272 | 0.050 |
Why?
| Genotype | 2 | 2014 | 539 | 0.050 |
Why?
| Lipids | 2 | 2014 | 145 | 0.050 |
Why?
| Staphylococcus aureus | 2 | 2015 | 327 | 0.050 |
Why?
| Glycoproteins | 2 | 2013 | 115 | 0.050 |
Why?
| Fatty Acids | 2 | 2012 | 143 | 0.050 |
Why?
| Blood Glucose | 2 | 2013 | 432 | 0.040 |
Why?
| Cytokines | 2 | 2014 | 607 | 0.040 |
Why?
| Swine | 2 | 2011 | 396 | 0.040 |
Why?
| Receptors, LDL | 1 | 2019 | 67 | 0.040 |
Why?
| Apoptosis | 2 | 2015 | 1092 | 0.040 |
Why?
| NF-kappa B | 2 | 2010 | 315 | 0.040 |
Why?
| Organ Specificity | 1 | 2018 | 106 | 0.040 |
Why?
| Toxicity Tests | 1 | 2018 | 54 | 0.040 |
Why?
| RNA, Ribosomal, 16S | 1 | 2018 | 111 | 0.040 |
Why?
| Computational Biology | 1 | 2019 | 214 | 0.040 |
Why?
| Muscle Fibers, Skeletal | 1 | 2018 | 63 | 0.040 |
Why?
| Acrylates | 1 | 2017 | 3 | 0.040 |
Why?
| Metabolomics | 1 | 2018 | 131 | 0.040 |
Why?
| Intestines | 1 | 2018 | 169 | 0.040 |
Why?
| Coal | 1 | 2016 | 1 | 0.040 |
Why?
| Glycosylation | 1 | 2016 | 102 | 0.030 |
Why?
| Taurochenodeoxycholic Acid | 1 | 2016 | 1 | 0.030 |
Why?
| Hydroxycholesterols | 1 | 2016 | 9 | 0.030 |
Why?
| Phosphatidylcholines | 1 | 2016 | 24 | 0.030 |
Why?
| Food-Drug Interactions | 1 | 2016 | 14 | 0.030 |
Why?
| Molecular Conformation | 1 | 2016 | 66 | 0.030 |
Why?
| Enzyme Induction | 1 | 2016 | 79 | 0.030 |
Why?
| Risk Factors | 2 | 2015 | 3605 | 0.030 |
Why?
| Debridement | 1 | 2015 | 44 | 0.030 |
Why?
| Dietary Supplements | 1 | 2019 | 437 | 0.030 |
Why?
| Drug Delivery Systems | 1 | 2017 | 143 | 0.030 |
Why?
| Leukocyte Count | 1 | 2015 | 71 | 0.030 |
Why?
| Systole | 1 | 2015 | 71 | 0.030 |
Why?
| Transaldolase | 1 | 2015 | 1 | 0.030 |
Why?
| Uridine Monophosphate | 1 | 2015 | 4 | 0.030 |
Why?
| Polyethylene Glycols | 1 | 2015 | 85 | 0.030 |
Why?
| Threonine | 1 | 2015 | 14 | 0.030 |
Why?
| Heme | 1 | 2015 | 21 | 0.030 |
Why?
| Lipid Peroxidation | 1 | 2015 | 96 | 0.030 |
Why?
| Diet, Fat-Restricted | 1 | 2015 | 12 | 0.030 |
Why?
| Open Reading Frames | 1 | 2015 | 54 | 0.030 |
Why?
| Myocardial Contraction | 1 | 2015 | 110 | 0.030 |
Why?
| Bronchi | 1 | 2015 | 43 | 0.030 |
Why?
| Administration, Oral | 1 | 2016 | 433 | 0.030 |
Why?
| Gene Silencing | 1 | 2015 | 114 | 0.030 |
Why?
| Imidazoles | 1 | 2015 | 128 | 0.030 |
Why?
| Hep G2 Cells | 1 | 2014 | 36 | 0.030 |
Why?
| Brachiocephalic Trunk | 1 | 2014 | 6 | 0.030 |
Why?
| Coal Mining | 1 | 2014 | 4 | 0.030 |
Why?
| Ventricular Dysfunction, Left | 1 | 2015 | 101 | 0.030 |
Why?
| Protein Structure, Quaternary | 1 | 2014 | 27 | 0.030 |
Why?
| Protein Engineering | 1 | 2014 | 18 | 0.030 |
Why?
| Amino Acid Motifs | 1 | 2014 | 57 | 0.030 |
Why?
| Nitrophenols | 1 | 2014 | 17 | 0.030 |
Why?
| Biocatalysis | 1 | 2014 | 14 | 0.030 |
Why?
| Receptor, TIE-2 | 1 | 2014 | 16 | 0.030 |
Why?
| Carbohydrates | 1 | 2014 | 40 | 0.030 |
Why?
| 3T3-L1 Cells | 1 | 2013 | 12 | 0.030 |
Why?
| Naphthols | 1 | 2013 | 9 | 0.030 |
Why?
| Integrases | 1 | 2014 | 43 | 0.030 |
Why?
| Transgenes | 1 | 2014 | 52 | 0.030 |
Why?
| Cyclization | 1 | 2013 | 5 | 0.030 |
Why?
| Glutarates | 1 | 2013 | 6 | 0.030 |
Why?
| Escherichia coli | 1 | 2015 | 191 | 0.030 |
Why?
| Stereoisomerism | 1 | 2013 | 101 | 0.030 |
Why?
| Mice, Inbred NOD | 1 | 2013 | 94 | 0.030 |
Why?
| Micromonospora | 1 | 2013 | 1 | 0.030 |
Why?
| Enediynes | 1 | 2013 | 1 | 0.030 |
Why?
| Motor Activity | 1 | 2015 | 221 | 0.030 |
Why?
| Salmonella enterica | 1 | 2013 | 17 | 0.030 |
Why?
| DNA Primers | 1 | 2013 | 208 | 0.030 |
Why?
| Talin | 1 | 2013 | 3 | 0.030 |
Why?
| Stress, Physiological | 1 | 2014 | 173 | 0.030 |
Why?
| Integrin beta Chains | 1 | 2013 | 13 | 0.030 |
Why?
| Chemotactic Factors | 1 | 2013 | 5 | 0.030 |
Why?
| Cathelicidins | 1 | 2013 | 1 | 0.030 |
Why?
| Epithelial Cells | 1 | 2015 | 209 | 0.030 |
Why?
| Superoxide Dismutase | 1 | 2013 | 113 | 0.030 |
Why?
| beta-Defensins | 1 | 2013 | 4 | 0.030 |
Why?
| Caspases | 1 | 2013 | 104 | 0.030 |
Why?
| Regenerative Medicine | 1 | 2013 | 10 | 0.030 |
Why?
| Cell Growth Processes | 1 | 2013 | 22 | 0.030 |
Why?
| HSP90 Heat-Shock Proteins | 1 | 2013 | 51 | 0.030 |
Why?
| Drug Screening Assays, Antitumor | 1 | 2013 | 131 | 0.030 |
Why?
| Receptors, CXCR4 | 1 | 2013 | 27 | 0.030 |
Why?
| Receptors, Purinergic P2Y | 1 | 2012 | 3 | 0.030 |
Why?
| Methionine | 1 | 2014 | 133 | 0.030 |
Why?
| Aorta | 1 | 2014 | 162 | 0.030 |
Why?
| Epoprostenol | 1 | 2012 | 25 | 0.030 |
Why?
| Isotope Labeling | 1 | 2013 | 52 | 0.030 |
Why?
| Adenosine Diphosphate | 1 | 2012 | 21 | 0.030 |
Why?
| Neointima | 1 | 2012 | 5 | 0.030 |
Why?
| Chemokine CXCL12 | 1 | 2013 | 30 | 0.030 |
Why?
| Antigens, CD34 | 1 | 2013 | 65 | 0.030 |
Why?
| Diet, Atherogenic | 1 | 2012 | 8 | 0.030 |
Why?
| Mice, Obese | 1 | 2012 | 20 | 0.030 |
Why?
| rho-Associated Kinases | 1 | 2012 | 20 | 0.030 |
Why?
| Microfilament Proteins | 1 | 2012 | 42 | 0.030 |
Why?
| Cell Hypoxia | 1 | 2013 | 82 | 0.030 |
Why?
| Mice, Mutant Strains | 1 | 2012 | 71 | 0.030 |
Why?
| Staphylococcal Infections | 1 | 2015 | 269 | 0.030 |
Why?
| Adaptor Proteins, Signal Transducing | 1 | 2013 | 197 | 0.030 |
Why?
| Cross-Sectional Studies | 1 | 2018 | 1576 | 0.030 |
Why?
| Carotid Artery, Common | 1 | 2012 | 44 | 0.030 |
Why?
| Cyclic AMP | 1 | 2012 | 92 | 0.030 |
Why?
| Hyperplasia | 1 | 2012 | 96 | 0.030 |
Why?
| Lysine | 1 | 2013 | 83 | 0.030 |
Why?
| Gene Expression Regulation, Bacterial | 1 | 2014 | 189 | 0.030 |
Why?
| Cell Adhesion Molecules | 1 | 2012 | 87 | 0.030 |
Why?
| Extracellular Signal-Regulated MAP Kinases | 1 | 2012 | 81 | 0.030 |
Why?
| Gene Expression | 1 | 2015 | 612 | 0.030 |
Why?
| Saccharomyces cerevisiae | 1 | 2013 | 178 | 0.030 |
Why?
| Embryonic Stem Cells | 1 | 2012 | 15 | 0.030 |
Why?
| Adipokines | 1 | 2012 | 10 | 0.030 |
Why?
| Insulinoma | 1 | 2012 | 7 | 0.030 |
Why?
| Microbial Sensitivity Tests | 1 | 2013 | 271 | 0.030 |
Why?
| Neoplasm Metastasis | 1 | 2013 | 235 | 0.030 |
Why?
| Paxillin | 1 | 2012 | 6 | 0.030 |
Why?
| Embryo, Mammalian | 1 | 2012 | 67 | 0.030 |
Why?
| Oncogene Protein v-akt | 1 | 2012 | 10 | 0.030 |
Why?
| Neoplasm Invasiveness | 1 | 2013 | 268 | 0.030 |
Why?
| Phosphoproteins | 1 | 2012 | 111 | 0.030 |
Why?
| Blood Vessels | 1 | 2012 | 71 | 0.030 |
Why?
| Injections, Intraperitoneal | 1 | 2012 | 54 | 0.020 |
Why?
| Subcutaneous Fat | 1 | 2012 | 19 | 0.020 |
Why?
| Proto-Oncogene Proteins c-akt | 1 | 2012 | 155 | 0.020 |
Why?
| Focal Adhesion Kinase 1 | 1 | 2012 | 15 | 0.020 |
Why?
| Lyases | 1 | 2011 | 2 | 0.020 |
Why?
| Lipogenesis | 1 | 2012 | 29 | 0.020 |
Why?
| Proto-Oncogene Proteins c-met | 1 | 2012 | 19 | 0.020 |
Why?
| Bone and Bones | 1 | 2015 | 473 | 0.020 |
Why?
| Dyslipidemias | 1 | 2012 | 36 | 0.020 |
Why?
| Lipoproteins, HDL | 1 | 2011 | 18 | 0.020 |
Why?
| Transfection | 1 | 2012 | 354 | 0.020 |
Why?
| Disease Susceptibility | 1 | 2012 | 88 | 0.020 |
Why?
| Blood Preservation | 1 | 2011 | 26 | 0.020 |
Why?
| Vinculin | 1 | 2011 | 3 | 0.020 |
Why?
| Myocardial Ischemia | 1 | 2013 | 117 | 0.020 |
Why?
| Lymphocytes | 1 | 2012 | 154 | 0.020 |
Why?
| HCT116 Cells | 1 | 2011 | 23 | 0.020 |
Why?
| Prospective Studies | 1 | 2018 | 2345 | 0.020 |
Why?
| Antigens, CD | 1 | 2013 | 215 | 0.020 |
Why?
| Gene Knockdown Techniques | 1 | 2012 | 106 | 0.020 |
Why?
| Ion Channels | 1 | 2012 | 74 | 0.020 |
Why?
| Mitochondrial Proteins | 1 | 2012 | 88 | 0.020 |
Why?
| Exons | 1 | 2011 | 96 | 0.020 |
Why?
| Fibronectins | 1 | 2011 | 38 | 0.020 |
Why?
| Promoter Regions, Genetic | 1 | 2014 | 467 | 0.020 |
Why?
| Erythrocytes | 1 | 2011 | 83 | 0.020 |
Why?
| Cell Survival | 1 | 2013 | 590 | 0.020 |
Why?
| Caveolae | 1 | 2011 | 6 | 0.020 |
Why?
| Platelet Glycoprotein GPIIb-IIIa Complex | 1 | 2011 | 32 | 0.020 |
Why?
| Mice, Nude | 1 | 2012 | 252 | 0.020 |
Why?
| Xenograft Model Antitumor Assays | 1 | 2012 | 212 | 0.020 |
Why?
| Asthma | 1 | 2015 | 282 | 0.020 |
Why?
| Rotarod Performance Test | 1 | 2011 | 6 | 0.020 |
Why?
| Cell Adhesion | 1 | 2011 | 155 | 0.020 |
Why?
| Bilirubin | 1 | 2011 | 40 | 0.020 |
Why?
| Borohydrides | 1 | 2010 | 1 | 0.020 |
Why?
| Neuroprostanes | 1 | 2010 | 1 | 0.020 |
Why?
| Motor Skills | 1 | 2011 | 25 | 0.020 |
Why?
| Cyclopentanes | 1 | 2010 | 10 | 0.020 |
Why?
| Organ Culture Techniques | 1 | 2011 | 48 | 0.020 |
Why?
| In Situ Nick-End Labeling | 1 | 2011 | 52 | 0.020 |
Why?
| Dose-Response Relationship, Drug | 1 | 2014 | 1354 | 0.020 |
Why?
| Cytoprotection | 1 | 2010 | 34 | 0.020 |
Why?
| RNA-Binding Proteins | 1 | 2011 | 120 | 0.020 |
Why?
| Fatty Liver | 1 | 2012 | 126 | 0.020 |
Why?
| Superoxides | 1 | 2010 | 46 | 0.020 |
Why?
| Binding Sites | 1 | 2011 | 378 | 0.020 |
Why?
| Cell Count | 1 | 2011 | 147 | 0.020 |
Why?
| Lymph Nodes | 1 | 2012 | 257 | 0.020 |
Why?
| Phosphodiesterase I | 1 | 2010 | 1 | 0.020 |
Why?
| Cell Membrane | 1 | 2011 | 249 | 0.020 |
Why?
| Pyrophosphatases | 1 | 2010 | 13 | 0.020 |
Why?
| Oxadiazoles | 1 | 2010 | 10 | 0.020 |
Why?
| Cell Line | 1 | 2013 | 1010 | 0.020 |
Why?
| Multienzyme Complexes | 1 | 2010 | 35 | 0.020 |
Why?
| Lipolysis | 1 | 2010 | 11 | 0.020 |
Why?
| Inhibitory Concentration 50 | 1 | 2010 | 71 | 0.020 |
Why?
| COS Cells | 1 | 2010 | 73 | 0.020 |
Why?
| Albumins | 1 | 2010 | 30 | 0.020 |
Why?
| Drug Evaluation, Preclinical | 1 | 2010 | 145 | 0.020 |
Why?
| Oxidation-Reduction | 1 | 2010 | 315 | 0.020 |
Why?
| Risk Assessment | 1 | 2014 | 1255 | 0.020 |
Why?
| Endothelium, Vascular | 1 | 2011 | 251 | 0.020 |
Why?
| Protein Transport | 1 | 2010 | 183 | 0.020 |
Why?
| Pancreatic Neoplasms | 1 | 2012 | 209 | 0.020 |
Why?
| Liver Neoplasms | 1 | 2012 | 329 | 0.020 |
Why?
| Immunohistochemistry | 1 | 2011 | 972 | 0.020 |
Why?
| Lung Neoplasms | 1 | 2013 | 602 | 0.020 |
Why?
| Aged | 1 | 2011 | 9449 | 0.010 |
Why?
| Middle Aged | 1 | 2011 | 12293 | 0.010 |
Why?
| Adult | 1 | 2011 | 13356 | 0.010 |
Why?
|
|
Morris's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|